Brepocitinib Shows Efficacy in Uveitis Phase 3 Trials
The drug achieved steroid-free quiescence in 62% of patients, marking a key milestone for an upcoming regulatory filing in 2027.
Updated on Oct. 21, 2026 in Biotech
Live Poll
Should the government prioritize fast-tracking regulatory approval for new drug treatments for rare, debilitating diseases?
Roivant and Priovant have reported positive Phase 3 results for brepocitinib in treating non-infectious uveitis. The clinical program demonstrated statistically significant improvements in maintaining vision-threatening inflammation control compared to placebo.
Why it matters
These results provide a potential new therapeutic path for non-infectious uveitis, a condition that often requires long-term steroid use. The findings mark a critical step in moving toward a regulatory filing for this patient population.
In the 371-patient CLARITY program, the 45 mg daily dose of brepocitinib extended the median time to treatment failure beyond 48 weeks, compared to approximately 12 weeks for the placebo group.
The players
Roivant
A biopharmaceutical company that develops and commercializes medicines through a decentralized model.
Priovant
A subsidiary of Roivant focused on the development of novel therapies for autoimmune and inflammatory diseases.
The details
Patients in both arms of the trial underwent an 8-week corticosteroid regimen starting at 60 mg per day with a 6-week taper to zero. Brepocitinib acts as a small-molecule inhibitor of TYK2 and JAK1, enzymes involved in the intracellular signaling pathways that trigger inflammatory cytokines. Clinical investigators monitored for treatment failure, defined as persistent inflammation or disease worsening, to evaluate the drug's efficacy against standard-of-care tapering.
Timeline
October 21, 2026: Roivant hosted an investor call to discuss the trial results.
December 9, 2026: Roivant scheduled an investor day presentation.
First half of 2027: Priovant intends to file a supplemental New Drug Application.
The Tech Race
The CLARITY-1 and CLARITY-2 trials represent a significant advancement in the development of targeted JAK-inhibitor therapies for ocular inflammation. This milestone positions brepocitinib as a lead candidate for patients who are unable to maintain quiescence without systemic corticosteroids.
For patients with non-infectious uveitis, this therapy offers a potential alternative to long-term steroid dependence, which can cause significant side effects. The treatment is currently undergoing the final steps before a potential regulatory approval timeline is confirmed.
The takeaway
The CLARITY program suggests that TYK2 and JAK1 inhibition can maintain ocular quiescence for nearly a year in patients who would otherwise require chronic steroids. Investors and patients should track the upcoming supplemental New Drug Application filing targeted for early 2027.
What happens next
Priovant plans to file a supplemental New Drug Application with the FDA in the first half of 2027.
Further reading
For broader trends in novel inflammatory therapies, visit our Biotech section.
Live Poll
Should the government prioritize fast-tracking regulatory approval for new drug treatments for rare, debilitating diseases?
